Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
04 February 2021Website:
http://landosbiopharma.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Thu, 23 May 2024 20:41:13 GMTDividend
Analysts recommendations
Institutional Ownership
Included in screeners
LABP Latest News
Landos Biopharma (NASDAQ: LABP ) stock is on the rise Monday after the company announced an acquisition deal with AbbVie (NYSE: ABBV ). AbbVie is acquiring Landos Biopharma for $20.42 per share in cash.
What type of business is Landos Biopharma?
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis; NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1 (NOD-like), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and LABP-104, an orally-active and systemically bioavailable small molecule therapeutic candidate that targets LANCL2 agonist for the treatment of systemic lupus erythematosus and rheumatoid arthritis (RA). Its preclinical candidates in development include LABP-66 is an oral and small molecule NOD-like pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA; LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; and LABP-111, an oral and small molecule LANCL2 pathway agonist for the treatment of nonalcoholic steatohepatitis and type 1 diabetes. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.
What sector is Landos Biopharma in?
Landos Biopharma is in the Healthcare sector
What industry is Landos Biopharma in?
Landos Biopharma is in the Biotechnology industry
What country is Landos Biopharma from?
Landos Biopharma is headquartered in United States
When did Landos Biopharma go public?
Landos Biopharma initial public offering (IPO) was on 04 February 2021
What is Landos Biopharma website?
https://landosbiopharma.com
Is Landos Biopharma in the S&P 500?
No, Landos Biopharma is not included in the S&P 500 index
Is Landos Biopharma in the NASDAQ 100?
No, Landos Biopharma is not included in the NASDAQ 100 index
Is Landos Biopharma in the Dow Jones?
No, Landos Biopharma is not included in the Dow Jones index
When does Landos Biopharma report earnings?
The next expected earnings date for Landos Biopharma is 09 August 2024